hotspot -WSS

hotspot

author：knowledge 2025-09-03 07:53:15 - browse：77553

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid.

But what if long Covid isn’t the right way to think about what they are going through?

On this episode of the First Opinion Podcast, I spoke with Steven Phillips and Michelle A. Williams, authors of a recent First Opinion essay titled, “Long Covid is a new name for an old syndrome.” Steven is a Global Virus Network board member and vice president for science and strategy at the COVID Collaborative; Michelle is the former dean and current Joan and Julius Jacobson professor of epidemiology and public health at the Harvard T.H. Chan School of Public Health.

“Michelle and I have come up with basically a new paradigm that says long Covid is really an old disease, and the more you do deep dives into the history of chronic fatigue syndrome and post-infectious fatigue syndromes, the more you realize that not only are there similarities, but the level of congruence between the two is strikingly high,” Steven said.

The purpose of this new paradigm is to “break the logjam” of the current long Covid discourse and “to try to provide a framework whereby people would think about long Covid in a different way in a way that would be more productive,” Michelle told me.

We discussed the history of post-infectious disease syndrome, what rethinking long Covid might mean for research, and the ways the health care system fails chronically ill patients.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How medical schools plan to diversify without affirmative action

entertainment

WSS

Hospitals consider fixing cancer drug shortages on their own

House looks to weaken Medicare negotiation

PEPFAR is under serious threat — and so is global health

How to fix the rural physician shortage in the U.S.

Acelyrin, a rare IPO success, stumbles in its first big test

An inside look at PIPEs, biotech's buzzy new financing tool

focus

hotspot

leisure time

Jerome Adams on the need for new antivirals for Covid

FogPharma raises $145 million in rare Series E round

23andMe had bad news about my health. I wish a person had delivered it

How to fix the rural physician shortage in the U.S.

Hollywood unions extend contract negotiations for actors

Congress gives doctors Medicare pay bump

Dobbs anniversary: the lost opportunity of abortion as health care

FDA panel endorses Alnylam’s heart drug — after picking it apart

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How to make the FDA’s new prescription one

leisure time

Food makers tried to stack nutrition panel with preferred experts

Popular nasal decongestant doesn't actually relieve congestion

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

A Q&A with Aletha Maybank, AMA’s chief health equity officer

House looks to weaken Medicare negotiation

Clinical trials giant ICON acquires HumanFirst

entertainment

leisure time

focus

focus